News & Updates

All
Publications
Awards
News
Grannus Therapeutics Named Indianapolis Business Journal 20 Startups to Watch 2025
May 9, 2025
News

Grannus Therapeutics Named Indianapolis Business Journal 20 Startups to Watch 2025

The focus of IBJ’s 2025 Innovation Issue is startups

Read More
May 9, 2025
Grannus Therapeutics Named Indianapolis Business Journal 20 Startups to Watch 2025
News

Grannus Therapeutics Named Indianapolis Business Journal 20 Startups to Watch 2025

January 29, 2025
Assessment of Hsp90β-selective inhibitor safety and on-target effects
Publications

Assessment of Hsp90β-selective inhibitor safety and on-target effects

December 5, 2024
Grannus Therapeutics Named 2025 MIRA Awards Finalist
Awards

Grannus Therapeutics was Named MIRA Awards Finalist for 2025

October 20, 2022
Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors
Publications

Hsp90β inhibition upregulates interferon response and enhances immune..

February 11, 2021
The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition
Publications

The Development of Hsp90β-Selective Inhibitors to Overcome Detriments..

April 24, 2020
The molecular chaperone Hsp90α deficiency causes retinal degeneration by disrupting Golgi organization and vesicle transportation in photoreceptors
Publications

The molecular chaperone Hsp90α deficiency causes retinal degeneration by..

January 30, 2018
Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor
Publications

Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor

June 4, 2012
The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking
Publications

The hERG channel is dependent upon the Hsp90α isoform for maturation and..

September 25, 2003
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Publications

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90..

January 29, 2025
Publications

Assessment of Hsp90β-selective inhibitor safety and on-target effects

The heat shock protein 90 (Hsp90) family of molecular chaperones mediates the folding and activation of ~ 400 client proteins, many of which contribute to oncogenesis.

Read More
February 11, 2021
Publications

The Development of Hsp90β-Selective Inhibitors to Overcome Detriments..

April 24, 2020
Publications

The molecular chaperone Hsp90α deficiency causes retinal degeneration by..

January 30, 2018
Publications

Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor

August 1, 2024
Awards

Grannus Therapeutics Wins RALLY Pitch Competition

The Competition provides meaningful funding and connections for innovative startups

Read More
December 5, 2024
Awards

Grannus Therapeutics was Named MIRA Awards Finalist for 2025

May 9, 2025
News

Grannus Therapeutics Named Indianapolis Business Journal 20 Startups to Watch 2025

The focus of IBJ’s 2025 Innovation Issue is startups

Read More
October 20, 2025
News

Grannus Selected as Batch 1 Participant in Plug and Play Lifetech Accelerator Program